Launched today by Roche: a 21-strong academic powerhouse set to progress discovery in cancer immunotherapy

Celebrated today at a kick-off meeting in Washington DC, USA, the pharmaceutical company Roche, has just announced the creation of a global partnership powered by 21 academic centers and leading experts in cancer immunotherapy: immunotherapy Centres of Research Excellence (imCORE) Network.

Working in collaboration with scientists from Roche and Genentech, renowned researchers and physician-scientists in cancer immunotherapy from across the globe will join together to drive the application and extension of novel immune-based therapeutics to more tumor types as well as advance research into the cellular and molecular mechanisms modulating immune response to cancer.

Among the 21 different academic partners, VHIO and the Clinical University of Navarra are the only two to have been selected from within Spain. Commenting for VHIO News, Josep Tabernero, Director of VHIO and appointed Principal Investigator of VHIO´s participation in imCORE observed, “This unique network will significantly contribute to advancing anti-cancer immunological strategies as well as accelerate discovery aimed at ultimately benefiting patients who may stand to gain from novel immune agents as mono therapy or in combination. Only through such cross-border, multi-center initiatives will we spur the development and application of novel immunotherapies and strategies aimed at making personalized medicine more precise and accessible for an increasing number of patients”.

To discover more please see today´s announcement issued by Roche:

Roche launches imCORE™, a global network of cancer immunotherapy centres of excellence

• Research network of 21 academic centres from around the world to access and share technology, data and expertise to advance the science of cancer immunotherapy

• Roche will invest up to 100 million Swiss Francs to support basic and clinical research collaborations within the imCORE Network

Roche – 15 November, 2016 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today launched the global cancer immunotherapy Centres of Research Excellence (imCORE) Network. This network brings together many of the world’s leading scientific and clinical experts in cancer immunotherapy to collaborate in investigating the most promising new treatment approaches. The goal is to rapidly initiate pre-clinical and clinical research based on the latest scientific discoveries and to aggregate and share data to accelerate the search for cures for people with cancer. The imCORE Network will focus on identifying approaches to expand the number of people who benefit from cancer immunotherapy by exploring new ways to activate a person’s immune system to fight their cancer.

“We believe the fastest way to advance progress against cancer is through collaboration, and consistent with our values, the goal of imCORE is to facilitate access to new technologies and emerging data among the top researchers around the world,” said Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development. “imCORE represents our most recent commitment to collaborate with the global cancer community to further understand the biology and immunology of cancer and to develop new treatments that may one day offer a cure for people with cancer.’’

Roche will invest up to 100 million Swiss Francs to support basic and clinical research collaborations related to cancer immunotherapy. This investment is incremental to Roche’s on-going research and development of investigational medicines and treatment approaches in the field of cancer immunotherapy.

About the imCORE Network

imCORE is a global network of basic and clinical scientists from 21 leading academic research institutions in cancer immunotherapy who will work together with scientists from Roche and Genentech, a member of the Roche group in the United States, with the goal of developing potential cures for people with cancer. Roche is working in collaboration with the network on existing and new investigational medicines, diagnostic technologies and emerging data. The network will also closely collaborate to identify and prioritise the most promising new treatment approaches and to rapidly conduct clinical trials to accelerate progress in the field.

About Roche in cancer immunotherapy

For more than 50 years, Roche has been developing medicines with the goal to redefine treatment in oncology. Today, Roche is investing more than ever in our effort to bring innovative treatment options that help a person’s own immune system fight cancer.


Related Posts